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 Colitis-associated cancer (CAC) develops through complication of inflammatory 
bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn’s disease (CD). Currently, 
CACs can only be diagnosed by colonoscopy and biopsy, which are invasive and prone 
to sampling errors. In this study, the feasibility of using 
19
F MRI for earlier diagnosis of 
CAC development was investigated by serial imaging of inflammatory sites in the colon. 
In vivo MR imaging of CAC-induced mice showed patchy distributions of 
19
F signals on 
colon wall, and co-localization of 
19
F signal patches with dysplastic and inflammatory 
lesions were confirmed by ex vivo imaging. Histological scores of inflammation and 
dysplasia showed significant correlation with the intensity of 
19
F signals. Overall, 
19
F 
MRI was used for the first time to observe the early stage of carcinomatous change of 
inflammatory sites in the colon, which is expected to enable earlier diagnosis of CAC. 
Thewell established relationship between inflammation and cancer suggests that 
19
F MRI 
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1.1 Inflammatory Bowel Diseases (IBD) and Colitis-Associated Cancer (CAC) 
 The causal relationship between inflammation and cancer has been well 
established (Fig. 1) (1). Epidemiological studies of patients and genetically modified 
mice have shown that chronic inflammation increases the risk of developing many types 
of cancer including bladder, cervical, gastric intestinal and thyroid cancer(2, 3). In 
molecular perspective, the transcription factors such as NF-κB, STAT3, and HIF1α in 
tumor cells recruit the inflammatory cells, which then promote angiogenesis, tumor cell 
proliferation, survival, migration, and metastasis (2, 4, 5). While it is estimated that the 
underlying inflammation is linked to 15 - 20% of cancer mortality worldwide, 
appropriate treatment with anti-inflammatory agents has shown to decrease the incidence 
and mortality of several types of tumor (6, 7, 8).  
 The most representative relationship between inflammation and cancer is seen in 
colon through inflammatory bowel diseases (IBD) followed by the development of 
colitis-associated cancer (CAC). IBD such as ulcerative colitis (UC) and Crohn’s disease 
(CD) are prevalent chronic inflammatory disorders of intestine in the United States with 1 
- 1.5 million patients affected (9, 10). The chronic inflammation accompanied by IBD is 
characterized by infiltrated immune cells producing proinflammatory cytokines and 
reactive oxygen species which facilitate mutations in oncogenes and tumor suppressor 
genes such as p53, adenomatous polyposis coli (APC), and K-ras (11). Sustained 
inflammation accumulates these mutations in colonic epithelial cells and leads to the 




 CACs show several characteristics different from sporadic CRCs in developing 
stages (12). In molecular level, CRCs and CACs share similar molecular alterations, but 
the timing and frequency of these alterations are major difference. In CRC, loss of APC 
function occurs in early stage of the pathogenesis and leads to the progression of 
adenoma. The alteration of p53 gene function then follows to drive the carcinomatous 
change of the adenomas. In CAC, p53 plays more important role in the early event while 
the alteration of APC function is much less frequent than in CRC and occurs in the late 
stage of pathogenesis. In a macroscopic view, CRCs develop through the sequence of 
adenoma-carcinoma, in which adenomas are usually polypoid and focal. CACs, however, 
develop through the sequence of inflammation-dysplasia-carcinoma, and the dysplastic 
lesions are usually multifocal and flat (13), which makes the detection of lesions much 
more difficult and hinders the early diagnosis and treatment.  
 Previously, it was shown that the risk of CAC is directly correlated with the 
duration of IBD and severity of inflammation (14). Meta-analysis showed that the risk of 
developing CAC is 2% after 10 years of UC, 8% after 20 years, and 18% after 30 years 
(15, 16). In case of CD, the risk for CAC is 2.9% at 10 years of disease, which increases 
to 8.3% after 30 years (17, 18). Thus, IBD patients are recommended to take regular 
surveillance every 1 - 2 years after 8 - 10 years from the onset of disease. The high 
incidence rate in young ages between 16 and 30 years (19) and the increased risk for 








Figure 1. Mechanisms of inflammation-driven cancer development (Ref. 3). Epithelial 
cells and tissue stem cells are genetically altered by proinflammatory cytokines or free 
radicals, and chronic inflammatory mediators facilitate tumor promotion. The tumor-
initiated epithelial cells in turn produce inflammatory mediators which recruit more 













1.2 Current Diagnosis: Endoscopy and Biopsy 
 Most of the current diagnoses of IBD and colon cancer are based on endoscopy 
and mucosal biopsy (20, 21). For the diagnosis of IBD, endoscopy aids in distinguishing 
UC from CD and defining the patterns and extent of mucosal inflammation. Once the 
IBD is diagnosed, endoscopy accompanied by histological analysis of biopsies are used 
to observe the severity of inflammation involvement and make therapeutic decisions. 
Especially in long-term complication of IBD, endoscopy is indispensable for monitoring 
any development of dysplastic lesions which can further develop into invasive carcinoma. 
  Yet, current endoscopy has a limitation of low magnification which only allows 
the surveillance of mucosal surface and surrounding blood vessels (22). Microscopic 
abnormalities cannot be observed, and this limitation becomes a huge drawback in the 
diagnosis of colitis-associated neoplasms. Due to the similar morphology, differential 
diagnosis between raised colitis-associated neoplasm and sporadic colorectal adenoma 
based on macroscopic appearance is difficult (23, 24), while the former should be treated 
by colectomy and the latter by polypectomy (25). Since colitis-associated neoplasms are 
usually in flat mucosa, it was reported that 50% - 80% of dysplastic lesions rising from 
colitis are not visible by endoscopy (26). Thus mucosal biopsies must be taken and 
analyzed to detect any flat colitis-associated dysplastic lesions. Although specific 
guidelines for biopsy were suggested, such as performing at least 32 biopsies per 
surveillance and obtaining samples every 10 cm (27), still it is not free from sampling 
errors. 
 New endoscopic imaging techniques are being studied to overcome the limitations. 




mucosal surface (28), and narrow band imaging improves blood vessel imaging by 
adopting optical filters which narrow the bandwidth of spectral transmittance (29).  
Confocal laser endomicroscopy was recently introduced for in vivo imaging of mucosal 
layer with 1,000-fold magnification, capturing cellular and subcellular features of lesions 
(30). 
 Although these new technologies have shown much improvement in detection of 
colitis-associated neoplasia, they are high cost methods and still invasive imaging 
modalities which cause patient discomfort. Considering that the IBD patients should 
frequently undergo the surveillance for a long time, the cost and invasiveness are major 
issues to be solved. Thus, non-invasive imaging modality which detects inflammatory 
and dysplastic lesions and measures their severity is needed.  
 
1.3 Non-invasive Imaging of Inflammation 
 Chronic inflammation is caused by variety of reasons, including persistent injury 
and microbial infection, prolonged exposure to a toxic agent, and autoimmune diseases, 
in which the immune responses damage the host tissue and result in tissue injury and 
inflammation. A group of immune cells such as lymphocytes, plasma cells and 
macrophages infiltrate to the inflammatory sites and contribute on tissue destruction and 
repairing with fibrosis and angiogenesis (31). In case of IBD, the mucosal barrier is 
breached by infectious or toxic agent, and the immune cells in lamina propria are 
persistently exposed to the luminal bacteria which initiate and maintain the inflammatory 




represented by structural abnormalities such as goblet cell depletion, crypt loss, 
ulceration and erosion (33).  
 Positron emission tomography (PET) and computer tomography (CT) has been 
tested to non-invasively image colon and quantify inflammation by targeting high 
metabolic activity in inflammatory lesions (34). PET involves using 18-
fluorodeoxyglucose (
18
FDG) for measuring abnormal metabolism with high glycolytic 
rates in several diseases including malignancy, inflammation and infection (35). PET 
complemented with CT for anatomical context was shown to be effective in diagnosis of 
IBD with a good correlation between PET activity and severity of inflammation. 
However, PET involves a radioactive tracers and has high background and low spatial 
resolution.  
 Magnetic resonance imaging (MRI) was also evaluated as a possible non-invasive 
modality for monitoring IBD patients (36, 37). MRI overcomes the limitations of 
PET/CT, since it does not generate ionizing radiation and has high spatial and temporal 
resolution with sufficient soft tissue contrast. However, MRI of bowel is difficult due to 
the complex three dimensional anatomies and inhomogeneity of magnetic field. Previous 
studies on application of MRI in IBD diagnosis only used colon wall thickness as a 
parameter of disease activity, which can never be a thorough evaluation.  
 Recent advancements in nanotechnologies led to the development of novel 
contrast agents of MRI, such as superparamagnetic iron oxide (SPIO) nanoparticles and 
perfluorocarbon (PFC) nanoemulsions. Intracellular labeling of these contrast agents 
enables non-invasive visualization of cells of interest, which has been widely used in 




labeling immune cells and tracking them, the possibility of applications in 
immunotherapy and diagnosis of inflammatory diseases was also demonstrated (39). 
 
1.4 SPIO Nanoparticle 
 SPIO nanoparticles affect T2 with strong magnetic moment from ferrous and 
ferric oxide cores (40). This strong local magnetic perturbation affects the surrounding 
water protons and leads to signal loss on T2-weighted MR images. Thus, the cells labeled 
with SPIO nanoparticles are expressed as dark spots on MR images due to the negative 
contrast. Upon systemic injection, SPIO nanoparticles are taken up by cells from 
reticuloendothelial system (RES), such as blood monocytes and macrophages. This 
approach has been applied to broad range of inflammatory events, including graft 
rejection and atherosclerosis (41, 42). The involvement of macrophages in 
neuroinflammation has further broadened the application of SPIO nanoparticles into 
neural diseases such as stroke, multiple sclerosis and brain tumors (43 - 45). 
 Although SPIO nanoparticles turned out to be useful in imaging inflammatory 
sites, it is difficult to measure and quantify the severity of inflammation due to its non-
linear response to external magnetic field. Negative contrast also makes the interpretation 
of MR images difficult, especially in case of hemorrhage near to lung, bone or blood flow 
(46). Another challenge is that SPIO particles can remain in a region of interest even after 
the labeled cells die and generate false signal. These limitations should be overcome for 






1.5 PFCNanoemulsion and 
19
F MRI 
 PFC is a molecule with similar structure to common organic molecules except 
that all the hydrogen atoms are substituted by fluorine. It is one of the most biologically 
inert molecules ever produced so that no enzyme can metabolize PFC (47, 48). Still, PFC 
is non-toxic in vivo even at high doses due to its high hydrophobicity and lipophobicity 
(49). Most PFCs have high oxygen solubility, which initiated early biological application 
of PFCs as blood substitutes for human use (50, 51). Thus the safety issues have been 
well studied and PFC has high potential of clinical usage. 
 
19
F MRI with PFC emulsion as a probe is considered as a strong candidate for 
non-invasive imaging method for detecting inflammatory sites (39, 52, 53). Unlike 
1
H 
MRI with SPIO nanoparticle labeling, PFC emulsions function as tracer agents so that 
19
F 
MRI directly detects the 
19
F nuclei in labeled cells. The absence of endogenous 
19
F in 
biological tissues ensures that there is no background and the “hot spots” only represent 
the labeled cells. Since the 
19
F signal is directly proportional to the number of 
19
F atoms, 
the exact number of labeled cells in a region of interest can be quantified. Thus 
19
F MRI 
overcomes the complexity of 
1
H MRI interpretation and enables quantification of cell 
numbers, or severity of inflammation (54, 55).      
  Once PFC emulsions are intravenously injected, a subgroup of leukocytes 
including monocytes, macrophages, neutrophils, dendritic cells and B lymphocytes are 
labeled with macrophages internalizing most of the agents (56 - 59). Since macrophages 
are crucial mediators of chronic inflammation (60, 61), selectively labeling macrophages 




severity of inflammation in several diseases, such as pulmonary inflammation, multiple 
sclerosis, ischemia, tumor and IBD (52, 57, 58, 62, 63).  
 
1.6 Study Summary 
 In this study, 
19
F MRI was used for the first time to longitudinally image the 
inflammatory sites in mouse IBD model developing to dysplastic lesions. Azoxymethane 
(AOM) and dextran sulfate sodium (DSS) were used to induce CAC development in mice 
(64, 65). In vivo
19
F MRI showed the inflammatory sites on colon wall and ex vivo MRI 
was done to exactly co-localize the 
19
F signals with any inflammatory sites and 
development of CAC. To confirm that 
19
F signals represent higher severity of 
inflammation and risk of CAC development, histological grading of inflammation and 
dysplasia was done and correlated with normalized signal-to-noise ratio (SNR) of 
19
F 
images. Overall, this study demonstrates that 
19
F MRI is an effective non-invasive 
imaging modality for tracking inflammatory sites and thus for predicting future sites of 
CAC development. It is expected that this technique can be widely used in diagnosis and 












2.1 Mouse Model of CAC 
All the experimental procedures involving animals were approved by 
Institutional Animal Care and Use Committee (IACUC) at the Johns Hopkins 
University.For a mouse model that develops CAC, the protocol previously described was 
used (64, 65). Briefly, 8-week-old female A/J mice (n = 5) purchased from Jackson 
Laboratories (Bar Harbor, ME, USA) were intraperitoneally injected with 10mg/kg body 
weight of AOM (A2853, Sigma, St.Louis, MO, USA) at day 0. To ensure that tumors 
develop through IBD, DSS (160110, MP Biomedicals, Solon, OH, USA) was used to 
induce chronic inflammation in a colon. DSS was dissolved in drinking water (2.5% w/v) 
for mice every 3 weeks until week 7 (Fig. 2). Mice weights were measured every week 
until the animals were sacrificed. 
 
2.2 PFC Emulsion Administration 
Two days before the first in vivo MR imaging, mice were injected with 200μl of 
a commercially available perfluoro-15-crown-5-ether emulsion (VS-580H, Celsense, 
Pittsburgh, PA, USA) intravenously through a tail vein using 271/2G needle. The 
concentration of the emulsion is 200 mg/ml, and the diameter ranges from 145 to 165 nm 
according to the manufacturer. 
 
2.3 In vivo MR Imaging 
 Mice were imaged every 15 days from day 50 to day 110. Imaging was performed 








(BrukerBiospin, Billerica, MA, USA). The mice were anesthetized by 1.5% isoflurane 
gas and heart rate was monitored during the imaging sessions. 
1
H images were acquired 
using a rapid acquisition with refocused echoes (RARE) sequence (Parameters: Slice 
thickness = 2 mm, Matrix size= 256 x 256, RARE factor = 8, FOV = 3.2cm x 2.0cm, NA 
= 4, Repetition time (TR)/Echo time (TE) = 1200ms/30ms). 
19
F images were also 
acquired by the same sequence (Parameters: Slice thickness = 2 mm, Matrix size = 64 x 
32, RARE factor = 8, FOV = 3.2cm x 2.0cm, NA = 64, TR/TE = 1000ms/14ms). 
19
F 
images were expressed in pseudo color scale and superimposed to the corresponding 
1
H 
images. Each image was scaled for optimal visualization and presentation. 
 
2.4 Ex vivo MR Imaging 
 After the last in vivo MR imaging, the mice were euthanized and the colons were 
excised. Each colon was divided into two parts, ascending colon and descending colon, 
and a glass rod was inserted into the lumen of each colon segment to straighten the 
tissues. After fixation in 4% paraformaldehyde for 2 days, tissues were transferred to 
PBS and imaged with 750 MHz MR microimaging system and a 25mm-volume coil 









images were acquired using a RARE sequence (
1
H Parameters: Slice thickness = 1 mm, 
Matrix size = 256 x 256, RARE factor = 8, FOV = 2.60 cm x 1.30 cm for sagittal and 
1.30 x 1.30cm for axial images, NA = 4, TR/TE = 1000ms/10ms), and 
19
F images 
(Matrix size = 64 x 32, RARE factor = 16, NA = 256, TR/TE = 1000ms/6ms. Other 
parameters are same as 
1









FMR Signal Analysis 
 For analysis of 
19
F MR signal, ParaVision 5.1 software (BrukerBiospin) was used. 
Region of interest (ROI) was drawn on each
19
F signal patch on colon wall for measuring 
mean intensity. The standard deviation of the background intensity was also measured to 
calculate signal-to-noise ratio (SNR) of the selected 
19
F signal patch. Each 
19
F MR image 
was adjusted so that only the 
19
F signals with SNR of 3.5 or above remain and 
background noises are suppressed. SNR of 
1
H images were also calculated by the same 





H SNRs were used throughout the study as an indicator of 
signal intensity. 
 
2.6 Histological Grading of Inflammation and Dysplasia 
 Fixed colon tissues were washed with PBS and were cut longitudinally to 
investigate a possible tumor outgrowth. Colon tissues were further divided into multiple 
segments and classified into either segments with 
19
F signals or those without the signals. 
These segments were embedded in paraffin block and cut transversely into 5μm-thick 
sections, followed by hematoxylin and eosin (H&E) staining. The sections were analyzed 
by two pathologists blinded to the identity of samples. The degree of inflammation was 
scored based on the method proposed by Hogan et al. with some modification (66). 
Briefly, degree of inflammation was assessed in six categories which are 1) area involved, 
2) crypt loss, 3) erosion/ulceration, 4) edema, 5)polymorphonuclear cell (PMNC) 
infiltration and 6) mononuclear cell (MNC) infiltration. For area involved and crypt loss, 




above. Erosions and ulcerations were defined as 0, intact epithelium; 1, involvement of 
the lamina propria; 2, ulcerations involving the submucosa; and 3, transmural ulcerations. 
The rest of the parameters were scored as 0, absent; 1, weak; 2, moderate; 3, severe. Total 
colitis score was expressed as the sum of all scores from individual parameters. Any 
appearance of adenomas and dysplastic lesions was also graded based on their sizes and 



















Figure 2. Timeline of developing CAC mouse model. Single intraperitonealinjetion of 
azoxymethane (AOM) was made on day 0 with the first cycle of DSS started 
simultaneously. Each DSS cycle was a week-long, applied every three weeks until week 
7. On day 48, at the end of the last DSS cycle, PFC emulsions were intravenously 
injected through a tail vein and in vivo MR imaging was performed through day 50 to day 















3.1 In vivo MRI Shows Inflammatory Sites on Colon Wall 
Chronic inflammation was induced by a single injection of AOM and three 
cycles of DSS solution treatment (Fig.2). At the end of the last cycle of DSS treatment, 
PFC emulsion was injected to both CAC-induced and control group of mice. The in vivo 
imaging of mice was initiated 2 days after the PFC injection. 
19
F MRI showed PFC 
emulsions concentrated on a colon wall with patchy distribution (Fig. 3A). No 
19
F signals 
were detected from colon wall of mice that were not induced with CAC (Fig. 3B). Along 
with 
19
F signals, proliferative lesions started to be observed from CAC-induced mice on 
day 80. To investigate the change of 
19
F signal intensity over time, SNR of 
19
F signals on 
colon wall was normalized to the SNR of corresponding
1
H images. The normalized SNR 
showed that the 
19
F signal intensity kept decreasing over time, but the signals were 
detected up to day 110 when the mice were euthanized (Fig. 3C). Strong 
19
F signals were 

















F MR imaging shows PFC emulsion accumulation on colon walls 
and vertebra in mice. (A) Axial MR images of abdomen of CAC-induced mice from day 
50, 65, 80, 95, and 110 (from left to right). Panels in top row are 
1
H images in gray scale 
which show anatomical texture of mice abdomen. Middle row are 
19
F images in hot iron 




F merged images, showing that the 
19
F signals 
are coming from colon wall and vertebra (yellow and white arrows respectively). From 
day 80, proliferative lesions started to be detected along the 
19
F signals on colon wall 
(blue arrows). 
19




Axial MR images of control mice does not show 
19
F signals from colon wall but only 
from vertebra (white arrow). (C) Normalized 
19
F signal-to-noise ratio (SNR) shows that 
19
























3.2 Co-localization of 
19
F Signal with Inflammatory and Dysplastic Lesions Through Ex 
Vivo MRI 
After the last in vivo MRI, mice were euthanized and colon tissues were excised 
and fixed in 4% paraformaldehyde. Ex vivo MR imaging was done to confirm the results 
from in vivo MRI and exactly co-localize the inflammatory sites and dysplastic lesions 
with 
19
F signals. Similar to in vivo images, 
19
F signals were concentrated on the colon 
wall showing several distinct foci (Fig. 4A). Once the colon tissues were cut and opened 
longitudinally, most of descending colon segments with 
19
F signals contained adenomas 
or dysplastic lesions while all the colon segments without 
19
F signals did not have any 
kinds of proliferative lesions (Fig. 4B). H&E stained sections from paraffin-embedded 
tissues were compared with corresponding axial MR images. The strong 
19
F signals 
turned out to be coming from either regions with severe inflammation characterized by 












Figure 4. Ex vivo MR images show co-localization of 
19
F signals with adenoma and 
inflammatory sites. (A) Representative sagittal MR images of excised colon fixed in 4% 
paraformaldehyde. 
1
H images (gray scale) were merged with corresponding 
19
F images 
(hot iron scale) to identify the origination of 
19
F signals. White arrow indicates an 
adenoma grown from a 
19
F-positive inflammatory site. (B) Excised colons were grossly 
observed for comparison with corresponding MR images. Boxes of same color coding 
(red and blue) indicate the adenoma in thegross image of a colon segment and MR image. 
Both of these adenomas show 
19
F signals from MR image (scale unit: cm). (C) Axial ex 
vivo MR images were compared with corresponding regions on H&E stained sections. 
Co-localization of 
19































F Signal Intensity Has High Correlation with Histological Scores of Inflammation 
and Dysplasia  
 To confirm whether 
19
F signal indicates higher severity of inflammation and risk 
of CAC development, histological sections of colon tissues were analyzed (Fig. 5A). 
Multiple colon segments from each CAC-induced mouse were made and classified to 
either segments with 
19
F signal or those without 
19
F signal. Inflammation in H&E stained 
sections were analyzed through six parameters, which are 1) area involved, 2) edema, 3) 
crypt loss, 4) erosion, 5) polymorphonuclear cell (PMNC) infiltration, and 6) 
mononuclear cell (MNC) infiltration into lamina propria. Dysplastic lesions were also 
scored based on their sizes and invasiveness.  
 In most of the parameters, sections from colon segments with 
19
F signal had 
higher scores than those without the signals, with especially significant difference 
observed in MNC infiltration criteria (Fig. 5B). Dysplasia scores and total colitis score, 
the sum of scores from all criteria, were also compared between two groups, and 
segments with 
19
F signal had significantly higher scores in both cases (Fig. 5C). 
Comparison between the segments from ascending colon and from descending colon 
showed that the latter group had higher score (Fig. 6A).  
 For the segments with 
19
F signal, the normalized 
19
F SNRs were correlated with 
histological scores of colitis and dysplasia. Segments from both ascending colon and 
descending colon showed a significant correlation with the total colitis score (Fig 6B,C). 
To confirm that severe inflammation has high risk of developing dysplasia, descending 




dysplasia. Dysplasia groups had significantly higher total colitis score and normalized 
19
F 




















Figure 5. Representative H&E (hematoxylin& eosin)-stained sections from colons and 
inflammation scores of colon segments. (A) H&E stained sections of colon segments 
from 1) control mouse, 2) CAC-induced mouse but without 
19
F signal, 3) CAC-induced 
mouse with 
19
F signal, and 4) adenoma with 
19
F signal (from left to right). Sections of 
segments with 
19
F signal shows much more inflammation than those without 
19
F signal, 
characterized by significant leukocyte infiltration and thick colon wall (scale bar = 
200μm). (B) Colon segments with 
19
F signal (gray) has higher histological scores than 
segments without the signal (black) from most of the parameters. Significant differences 
were observed in area involved (p = 0.008) and mononuclear cell (MNC) infiltration (p = 
0.007) criteria. (C) Total colitis score was calculated by sum of the scores from all of 
criteria. Colon segments with 
19
F signals have significantly higher total colitis score (p = 
0.003) and dysplasia score (p = 0.004) than those without the signal. One-tailed t-test was 






Figure 6. Correlation between normalized 
19
F SNR and histological disease scores. (A) 
Comparison of total colitis score between ascending colon and descending colon. 
Descending colon shows much higher score than ascending colon (p = 0.006). Within the 
descending colon, segments with 
19
F signal (gray) has significantly higher score than 
those without the signal (black) (p = 0.0002). (B) Correlation between normalized 
19
F 
SNR and total colitis score of ascending colon segments (R
2 
= 0.673). (C) Correlation 
between normalized 
19
F SNR with the total colitis score in descending colon segments 
(R
2 
= 0.652). (D) Total colitis scores of descending colon segments either with dysplasia 
or without dysplasia (p = 0.0004). (E) Normalized 
19
F SNRs of descending colon 
segments either with dysplasia or without dysplasia (p = 0.002). One-tailed t-test was 





In this study, for the first time, 
19
F MRI was used to image the transition of 
inflammatory sites into dysplastic lesions, and the clinical potential of 
19
F MRI for earlier 
non-invasive CAC diagnosis has been demonstrated. The in vivo MR images showed 
19
F 
signals on colon wall with patchy distribution, representing accumulation of macrophages 
on inflammatory sites. The in vivo data were validated by ex vivo images and H&E 
stained sections, which showed exact co-localization with dysplastic lesions and 
19
F-
positive inflammatory sites. Histological scores of inflammation and dysplasia showed 
significant correlation with the intensity of 
19
F signals, indicating that the severity of 
inflammation can be non-invasively measured. 
 The accumulation of in situlabeled macrophages in inflammatory sites was 
represented by a patchy distribution of 
19
F signals on colon wall. These 
19
F signal patches 
enabled exact localization of inflammatory sties and measuring their severity, suggesting 
the possible utility of 
19
F MRI for making therapeutic decisions and more selective 
treatment of colitis and CAC through intraoperative image guidance. Since PFC 
emulsions label most of the circulating leukocytes and tissue macrophages, other sites in 
mouse body such as spleen, liver, and vertebra (bone marrow) that naturally contain high 
number of macrophages also showed high 
19
F signals (67, 68). Although 
19
F MRI 
requires longer time of acquisition (TA) than 
1
H MRI due to the lower sensitivity, the 




F imaging per mouse in this study was around 15 minutes, which is 
reasonable in both preclinical and clinical studies.   
 For accurate measurement of 
19
F signal intensity, 
19
F SNR was normalized to the 
SNR of corresponding
1




control such as coil sensitivity, field homogenization and receiver gain can be corrected 
through the normalization, and comparison of 
19
F signal intensities among animals and 
various days can be made. The normalized 
19
F SNR from in vivo imaging showed that 
there was a steady decrease in 
19
F signal over time, while tumor development started to 
be observed from day 80 (Fig. 3B). This decrease in 
19
F signal intensity may indicate the 
recovery from inflammation due to the termination of DSS administration, but further 
studies are needed to fully illuminate the reason and implication of decrease in 
19
F signal 
intensity over time. 
 The correlation of normalized 
19
F SNR to histological disease scores showed that 
19
F signals accurately represent the severity of inflammation and dysplasia development. 
The segment with 
19
F signals had higher scores from most of the criteria used for 
inflammation assessment than those without the signals. The most significant difference 
was observed in MNC infiltration criteria, while PMNC infiltration criteria did not show 
a significant difference. This phenomenon also supports the selective in situ PFC 
emulsion labeling of macrophages. Total colitis score, which is sum of the scores from all 
criteria, was also well represented by normalized 
19
F SNR. Total colitis scores of 
segments from a descending colon were significantly higher than those from an 
ascending colon (Fig. 6A). Previous studies have shown that descending colon is much 
more damaged than ascending colon upon DSS treatment and more susceptible to tumor 
growth (65). All the adenomas and dysplastic lesions appeared in this study were also 
from the descending colon.  
 Further analysis of the colon segments with 
19
F signal showed that 
19
F signals in 




total colitis score, indicating normalized 
19
F SNR well represents the severity of 
inflammation. Descending colon segments were further analyzed by comparing the 
segments with dysplasia and without dysplasia. The former group showed significantly 
higher total colitis score and normalized 
19
F SNR, showing the potential of finding 
dysplastic lesions depending on the intensity of 
19
F signals. Thus, 
19
F signals indicate not 
just the severity of inflammation but also the progress to dysplastic lesions. 
 Early diagnosis leads to the most effective treatment of cancer. As CAC is known 
to have lower survival rate than sporadic colorectal cancer, earlier diagnosis is even more 
crucial (69). Currently, colonoscopy and mucosal biopsy are widely used for diagnosis of 
bowel diseases and detection of tumor development. However, this method is invasive 
and time-consuming, which makes patients hesitate for frequent monitoring. PET/CT has 
been studied for non-invasive imaging of inflammation and tumor development, but it 
involves radiation and spatial resolution is low. Since 
19
F MRI is non-invasive and 
depends on macrophage infiltration rather than the macroscopic appearance of lesions, it 
overcomes the limitations of previous imaging methods and enables earlier diagnosis. 
 Overall, IBD significantly increases the risk of developing CAC. 
19
F MRI has a 
potential of predicting CAC development by tracking inflammatory sites and dysplastic 
lesions in the colon. Considering the functional relationship between inflammation and 
cancer, it is expected that 
19
F MRI can also be used in earlier diagnosis of many types of 







5. Future Studies 
 Although tracking macrophage burden can be used to measure the severity of 
inflammation, PFC emulsions can remain at the site even after macrophages leave or die 
and generate false signal. Thus, another marker for inflammation and tumor development 
should be assessed. Perfluoro-15-crown-5-ether emulsion used in this study enables 
measuring pO2 of the labeled cells and tissues by its T1 relaxation rate change depending 
on oxygen concentration (70, 71). Since hypoxia is accompanied by inflammation and 
tumor progression (72 - 74), measuring pO2 and following its dynamics over time 
through 
19
F MR will provide additional information on diagnosis of CAC development. 
 Intracellular labeling with nanoparticles does not affect cellular functions in most 
cases. However, one study showed that SPIO nanoparticle labeling of macrophages affect 
the cytokine production, changing the phenotype of macrophages to be anti-inflammatory 
(75). For mesenchymal stem cells, the differentiation lineage was affected by inhibition 
of chondrogenesis (76). Considering that PFC is used for anti-inflammatory agent for 
pulmonary diseases (77), there is a possibility that PFC emulsion labeling of 
macrophages can also perturb their original function.  
 One of the interesting observations from this study is that the 
19
F signals from in 
vivo images kept decreasing over time. Since dysplastic lesions have been developing 
during this period, the decrease of 
19
F signal itself may represent the transition from 
inflammation to dysplastic lesions. To further investigate, cohort of mice can be 
sacrificed at several time points and the colons can be histologically analyzed to observe 
the disease state and correlated with 
19
F signals.  




incorporating lipophilic drugs in lipid surfactants or conjugating the surface with 
targeting moieties or ligands (78). Recently, celecoxib, a cyclooxygenase-2 (COX-2) 
specific inhibitor, has been incorporated into PFC nanoemulsion to change the phenotype 
of macrophages from tumor-promoting to tumor-suppressing (79). This new theranostic 
method can be used to mitigate the severe inflammatory response and prevent tumor 
progression.     
 In summary, 
19
F MRI of PFC emulsions have a high potential of being used for 
thorough evaluation and therapy of tumor progression from inflammatory sites. Degree of 
hypoxia, which is also a marker of inflammation and tumor development, can be 
measured along with 
19
F signal intensity, and PFC emulsions can be rendered as a 
theranostic agent. All these measurements and observations can be done non-invasively, 
overcoming the inconvenience of current IBD and CAC diagnosis based on endoscopy 
and biopsy. Further studies will polish the new 
19
F MRI method described here and 
enable clinical application to enhance the diagnosis and treatment of inflammation-driven 
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